Research Analysts Offer Predictions for BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Wednesday, February 26th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will post earnings per share of ($3.55) for the year, down from their previous estimate of ($3.34). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.16. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm had revenue of $30.00 million during the quarter, compared to analyst estimates of $16.47 million. During the same quarter in the previous year, the firm earned $1.73 earnings per share. The firm’s revenue for the quarter was down 90.5% compared to the same quarter last year.

A number of other brokerages also recently commented on BEAM. Guggenheim restated a “buy” rating and issued a $78.00 target price on shares of Beam Therapeutics in a research note on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Beam Therapeutics in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday, February 3rd. Sanford C. Bernstein upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Finally, Leerink Partners upgraded shares of Beam Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the company from $27.00 to $39.00 in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $50.90.

Beam Therapeutics Stock Down 2.8 %

Shares of NASDAQ:BEAM opened at $27.11 on Friday. The company has a market cap of $2.24 billion, a PE ratio of -15.40 and a beta of 1.92. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $45.79. The firm has a 50-day simple moving average of $27.23 and a 200 day simple moving average of $25.92.

Hedge Funds Weigh In On Beam Therapeutics

Hedge funds have recently made changes to their positions in the business. Wealthfront Advisers LLC acquired a new stake in Beam Therapeutics during the fourth quarter valued at approximately $41,000. GF Fund Management CO. LTD. acquired a new stake in shares of Beam Therapeutics during the 4th quarter valued at $43,000. Sterling Capital Management LLC lifted its position in shares of Beam Therapeutics by 816.0% during the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock valued at $60,000 after acquiring an additional 2,146 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Beam Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock worth $75,000 after acquiring an additional 524 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Beam Therapeutics by 84.0% in the 3rd quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock worth $73,000 after acquiring an additional 1,431 shares during the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Insider Buying and Selling

In related news, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the transaction, the chief executive officer now owns 908,659 shares of the company’s stock, valued at $24,306,628.25. This trade represents a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the transaction, the insider now directly owns 102,968 shares in the company, valued at approximately $2,541,250.24. The trade was a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.